SLU-PP-332 Research Evidence
The SLU-PP-332 evidence base: trials, journals, and what the data does not yet show.
A Consistent Mouse-Model Signal
Billon et al. (2024, J Pharmacol Exp Ther) found SLU-PP-332 reduced body weight (~12%) and fat-mass accumulation in diet-induced-obese mice without reducing food intake. A companion 2023 study (ACS Chem Biol) found it increased oxidative type IIa muscle fibers and mitochondrial content — consistent with a genuine endurance-training-like metabolic shift, at least in mice.
Regulatory and Legal Status
SLU-PP-332 is not FDA-approved and has never been studied in humans as of 2026 — every claim rests on mouse and cell data. It is sold exclusively as a research-grade compound (RUO). Researchers and users should verify the legal status of SLU-PP-332 in their jurisdiction prior to purchase or use, and should weigh the complete absence of human data accordingly.
Trials and reviews
- Billon metabolic syndromeJ Pharmacol Exp Ther2024
Reduced fat-mass accumulation, raised fatty-acid oxidation in obese mice
- Billon ERR agonist / exerciseACS Chem Biol2023
Increased oxidative type IIa fibers + mitochondrial content
References
- SLU-PP-332 pan-ERR agonist metabolic syndrome study · Billon C, et al. · 2024